{"schema_version":"secwatch.filing_event.v1","accession":"0001551306-23-000045","form_type":"8-K","ticker":"PGNY","cik":"0001551306","company_name":"Progyny, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.353892+00:00","generated_at":"2026-06-15T13:10:31.588425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Progyny Q1 revenue $258.4M (+50% YoY); raises FY2023 guidance","bullets":["Net income $17.7M ($0.18 diluted EPS) vs $5.0M ($0.05) in Q1 2022.","Adjusted EBITDA $46.4M (+87% YoY); margin expanded 350 bps to 17.9%.","FY2023 revenue guidance raised to $1.04-1.065B from prior range.","Clients grew to 379 (from 264) and covered lives to 5.34M (+36% YoY).","Fertility revenue $157.1M (+42%); pharmacy revenue $101.2M (+65%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-23-000045","json":"https://secwatch.observer/filing/0001551306-23-000045.json","markdown":"https://secwatch.observer/filing/0001551306-23-000045.md","text":"https://secwatch.observer/filing/0001551306-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130623000045/0001551306-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130623000045/pgny-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:10:31.588425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eda676bbd9077e07f594ae2f82728cbdf284f989","claim":"Progyny, Inc. reported first quarter of 2023 results: revenue $258.4 million, net income $17.7 million, EPS $0.18. Guidance raised.","evidence_excerpt":"Revenue was $258.4 million, a 50% increase as compared to the $172.2 million reported in the first quarter of 2022, primarily as a result of the increase in our number of clients and covered lives. • Fertility benefit services revenue was $157.1 million, a 42% increase from the $110.9 million reported in the first quarter of 2022. • Pharmacy benefit services revenue was $101.2 million, a 65% increase as compared to the $61.3 million reported in the first quarter of 2022. Gross profit was $58.6 million, an increase of 78% from the $32.9 million reported in the first quarter of 2022, primarily due to the higher revenue. Gross margin was 22.7%, an increase of 360 basis points from the 19.1% reported in the prior year period, primarily due to ongoing efficiencies realized in the delivery of our care management services . Net income was $17.7 million, or $0.18 income per diluted share, an increase of 256% as compared to the $5.0 million, or $0.05 income per diluted share, reported in the fi","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551306/000155130623000045/0001551306-23-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$258.4 million"},{"label":"Net income","value":"$17.7 million"},{"label":"EPS","value":"$0.18"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}